Denmark's Symphogen Breaks European Private Funding Record With €100m Haul
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo A/S and Essex Woodlands each put €35 million into the next-generation antibody play, securing its funding for five years.
You may also be interested in...
Archimedes Raises £65 million for Leap to U.S.
About a year after Novo A/S announced the launch of its Growth Equity Fund, the firm has found a home for its first significant investment, contributing £40 million of a £65 million ($100 million) round for privately-owned UK-based specialty pharma firm Archimedes Pharma. Participants describe this as the largest private European biopharma fundraising in the last 15 years.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.